Statement 8 Sep 2010

Maternal health MDG to WHO South East Asia region meeting

63rd WHO Regional Committee for South East Asia IFPMA Statement under agenda item 14, “Accelerating the achievement of MDG5: addressing inequity in maternal and neonatal health”. Delivered by Mr. Mario Ottiglio, Associate Director, Public Affairs & Global Health On behalf of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), I would like to thank...

Read more
Press release 3 Sep 2010

IFPMA study shows low overall seasonal influenza vaccine distribution, despite recent growth

A new IFPMA study 1 , announced today at the “Options for the Control of Influenza VII” conference in Hong Kong, shows that global vaccine coverage remains uneven and low overall, despite total distribution of seasonal influenza vaccines nearly doubling over the last six years. The study, which surveyed IFPMA influenza vaccine company members 2...

Read more
Statement 28 Jul 2010

Voluntary licenses and non-assert declarations

Actions by R&D pharmaceutical companies that facilitate access to medicines Background/Rationale: IFPMA member companies are committed to improving access to antiretrovirals (ARVs) for those who cannot afford them, particularly in Least Developed Countries (LDCs) and low-income countries (LICs). For many years, the pharmaceutical industry has created and delivered ARVs that have saved millions of lives in the global...

Read more
Press release 6 Jul 2010

IFPMA and WADA to cooperate in the fight against doping in sport

The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and the World Anti-Doping Agency (WADA) signed a Joint Declaration on Cooperation in the Fight against Doping in Sport today in Lausanne, Switzerland. The Declaration was signed by Mr. David Howman, Director General of WADA, and Mr. Haruo Naito, President of the IFPMA and President and...

Read more
Statement 24 Jun 2010

Improving responses to future influenza pandemics

Improving Responses to Future Influenza Pandemics Lessons from the 2009-10 H1N1 Pandemic The 2009-10 H1N1 influenza pandemic prompted the most robust and complete pandemic response ever. As with any major public health initiative of this scale, it is important that stakeholders undertake a careful analysis of the response. This will help enhance future preparedness, by building on those...

Read more
Video 14 Jun 2010

IFPMA’s address at UN General Assembly on MDGs

On June 14, 2010, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) delivered a formal statement to the United Nations General Assembly Hearings with NGOs, Civil Society and the Private Sector on the UN Millennium Development Goals. The IFPMA, the only industry body selected to make such a statement, outlined its members’ major contributions...

Read more
Press release 14 Jun 2010

UN General Assembly informed of R&D pharmaceutical industry’s substantial contributions to millennium development goals

The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) today delivered a formal statement 1 to the United Nations General Assembly Hearings with NGOs, Civil Society and the Private Sector on the UN Millennium Development Goals. The IFPMA, the only industry body selected to make such a statement, outlined its members’ major contributions to the...

Read more
Press release 10 Jun 2010

New industry position requires submission for journal publication of all phase III clinical trials

Industry Commits to Submit for Scientific Journal Publication the Results of all its Phase III Clinical Trials The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) today approved a “Joint Industry Position on the Publication of Clinical Trial Results in the Scientific Literature” 1 , previously approved by the European Federation of Pharmaceutical Industries and...

Read more
Statement 21 May 2010

World Health Assembly on millennium development goals

UN Millennium Development Goals Statement by Mario Ottiglio, Advocacy & External Relations Manager, IFPMA, to the 63rd World Health Assembly under Agenda item 11.4, Monitoring the Achievement of the UN MDGs Honorable Ministers, Your Excellencies, Madame Director General, Ladies and Gentlemen, The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents the global R&D pharmaceutical industry, whose...

Read more
Statement 19 May 2010

World Health Assembly on counterfeits

Counterfeit Medical Products Statement by Eduardo Pisani, Director General of the IFPMA, to the 63rd World Health Assembly Honorable Ministers, Your Excellencies, Madame Director General, Ladies and Gentlemen, On behalf of the International Federation of Pharmaceutical Manufacturers and Associations, the IFPMA, I welcome the opportunity presented by the World Health Assembly to address the public health issue...

Read more
Statement 17 May 2010

World Health Assembly on pandemic influenza preparedness

IFPMA Statement under WHA 63 agenda item 11.1 on Pandemic influenza preparedness: sharing of influenza viruses and access to vaccines and other benefits Delivered by Eduardo Pisani, Director General, IFPMA Check against delivery Honorable Ministers, Your Excellencies, Madame Director General, Ladies and Gentlemen, The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents the global R&D pharmaceutical industry, whose...

Read more
Press release 12 May 2010

IFPMA launches ten principles on counterfeit medicines

Fight against Counterfeit Medicines to protect Patients’ Health    The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) today launched its Ten Principles on Counterfeit Medicines, to re-focus attention on this issue and underline the R&D-based pharmaceutical industry’s stance in the global fight against counterfeit medicines. Mr Haruo Naito, President of the IFPMA, and President...

Read more